NCT05074680View on ClinicalTrials.gov

COVID-19 Antibody Responses In Cystic Fibrosis

Active, not recruitingOBSERVATIONAL
Enrollment

5

Participants

Timeline

Start Date

February 14, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

July 31, 2025

Conditions
Cystic Fibrosis
Interventions
DIAGNOSTIC_TEST

Blood sampling

Blood serum samples will be collected for analysis of COVID-19 antibody levels. For participants who consent to the optional study, a second blood sample will also be drawn into EDTA tubes (plasma)

Trial Locations (2)

3010

University Children's hospital Bern, Bern

8032

University Children's hospital, Zürich, Zurich

All Listed Sponsors
collaborator

European Cystic Fibrosis Society

UNKNOWN

collaborator

Cystic Fibrosis Foundation

OTHER

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT05074680 - COVID-19 Antibody Responses In Cystic Fibrosis | Biotech Hunter | Biotech Hunter